Prev MonthPrev Month Next MonthNext Month
2021-04_FDA and the pandemic: What’s next, and what’s here to stay
Thursday, April 22, 2021, 6:30 PM - 8:00 PM EDT
Category: Events

The FDA has undergone significant changes and faced significant challenges during the pandemic. In this presentation, researchers from POLITICO’s regulatory intelligence division, AgencyIQ, will highlight some of the biggest changes made by the FDA and discuss how the agency is likely to change further in the near future.”



 Alexander Gaffney, MS, RAC

Alexander Gaffney is the Head of Research at POLITICO’s AgencyIQ, where he leads the team’s research and analysis of life sciences regulatory issues affecting the Food and Drug Administration. Alexander previously worked at PricewaterhouseCoopers where he led analysis of life sciences regulatory issues for the firm’s prestigious Health Research Institute. Before joining PwC, he was the Manager of Regulatory Intelligence at the Regulatory Affairs Professionals Society (RAPS), where he also was Managing Editor of the company’s flagship publication, Regulatory Focus. Alexander has a Master’s degree in Regulatory Science and his Regulatory Affairs Certification (RAC) in US regulation.


Kirsten Messmer, PhD, RAC

Kirsten Messmer, PhD, RAC is a Senior Research Analyst and contributes to the research and development of content for Agency IQ. Prior to joining Agency IQ, she was a Principal Regulatory Affairs Specialist at PPD providing global regulatory intelligence to support efficient, compliant and successful clinical research and drug development for biopharmaceuticals and advanced therapies. Kirsten received her PhD in Neuroscience from the University of Sheffield (Sheffield, UK) and a Biology Diplom from the Eberhard-Karls University (Tübingen, Germany). Kirsten also holds a Regulatory Affairs Certification (RAC) in US regulation.


Laura DiAngelo, MPH

Laura DiAngelo is a Senior Research Manager on the AgencyIQ team. She contributes to the research and development of content for Agency IQ, with an emphasis on medical device and diagnostics regulatory intelligence. Before joining POLITICO, Laura consulted on policy and regulatory issues for life sciences and health plan clients with Avalere Health, and managed content for the Avalere Policy and State Reform 360® business intelligence research products. She holds a MPH in health care policy from the George Washington University’s Milken School of Public Health.



Contact: [email protected]